MBX Biosciences, Inc. (NASDAQ:MBX) Given Average Rating of “Moderate Buy” by Brokerages

MBX Biosciences, Inc. (NASDAQ:MBX) has been given a consensus recommendation of “Moderate Buy” by the twelve ratings firms that are presently covering the stock, MarketBeat.com reports. Two analysts have rated the stock with a sell rating and ten have given a buy rating to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $51.5556.

Several research firms recently issued reports on MBX. TD Cowen began coverage on MBX Biosciences in a report on Tuesday, November 4th. They issued a “buy” rating on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of MBX Biosciences in a research report on Thursday, January 22nd. The Goldman Sachs Group began coverage on shares of MBX Biosciences in a report on Thursday, December 4th. They issued a “sell” rating and a $18.00 price objective for the company. Guggenheim increased their target price on shares of MBX Biosciences from $77.00 to $88.00 and gave the stock a “buy” rating in a report on Friday, January 16th. Finally, UBS Group reaffirmed a “buy” rating on shares of MBX Biosciences in a research report on Tuesday.

Institutional Trading of MBX Biosciences

A number of large investors have recently made changes to their positions in MBX. Sio Capital Management LLC acquired a new position in MBX Biosciences during the 2nd quarter worth approximately $2,750,000. Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in shares of MBX Biosciences during the third quarter worth $498,000. Resolute Capital Asset Partners LLC purchased a new position in MBX Biosciences in the second quarter valued at $567,000. Walleye Capital LLC raised its stake in MBX Biosciences by 116.5% in the second quarter. Walleye Capital LLC now owns 70,333 shares of the company’s stock valued at $802,000 after buying an additional 37,843 shares in the last quarter. Finally, Franklin Resources Inc. lifted its holdings in MBX Biosciences by 34.0% during the 2nd quarter. Franklin Resources Inc. now owns 494,852 shares of the company’s stock worth $5,646,000 after buying an additional 125,537 shares during the last quarter.

MBX Biosciences Trading Down 7.1%

Shares of NASDAQ MBX opened at $32.55 on Friday. The firm has a 50 day moving average price of $35.96. MBX Biosciences has a 52-week low of $4.81 and a 52-week high of $44.89. The stock has a market capitalization of $1.46 billion, a price-to-earnings ratio of -13.62 and a beta of 0.87.

About MBX Biosciences

We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our company was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, we designed our proprietary Precision Endocrine Peptide™, or PEPTM, platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients.